|United States Patent||RE43,279|
|Benner , et al.||March 27, 2012|
The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse renal reperfusion test, wherein the oligopeptide comprises the sequence AQG or MTRV (SEQ ID NO:1), AQGV (SEQ ID NO:2) or LAGV (SEQ ID NO:4).
|Inventors:||Benner; Robbert (Barendrecht, NL), Khan; Nisar Ahmed (Rotterdam, NL)|
|Filed:||March 17, 2011|
|Application Number||Filing Date||Patent Number||Issue Date|
|Reissue of:||11346450||Feb., 2006||7576174||Aug., 2009|
|Mar 29, 2000 [EP]||00201139|
|Current U.S. Class:||530/300 ; 530/330|
|Current International Class:||C07K 2/00 (20060101)|
|4977244||December 1990||Muchmore et al.|
|5010175||April 1991||Rutter et al.|
|5308834||May 1994||Scott et al.|
|5650489||July 1997||Lam et al.|
|5677275||October 1997||Lunardi-Iskandar et al.|
|5801193||September 1998||Ojo-Amaize et al.|
|5854004||December 1998||Czernilofsky et al.|
|5877148||March 1999||Lunardi-Iskandar et al.|
|5942494||August 1999||Ginsberg et al.|
|5958413||September 1999||Anagnostopulos et al.|
|5968513||October 1999||Gallo et al.|
|5997871||December 1999||Gallo et al.|
|6022696||February 2000||Harding et al.|
|6278794||August 2001||Parekh et al.|
|6319504||November 2001||Gallo et al.|
|6361992||March 2002||Szkudlinski et al.|
|6489296||December 2002||Grinnell et al.|
|6507788||January 2003||Camara y Ferrer et al.|
|6583109||June 2003||Gallo et al.|
|6586403||July 2003||Mathison et al.|
|6596688||July 2003||Gallo et al.|
|6620416||September 2003||Gallo et al.|
|6642201||November 2003||Khavinson et al.|
|6844315||January 2005||Khan et al.|
|6921751||July 2005||Khan et al.|
|7175679||February 2007||Khan et al.|
|7358330||April 2008||Khan et al.|
|7365155||April 2008||Khan et al.|
|7402322||July 2008||Khan et al.|
|7501391||March 2009||Khan et al.|
|7517529||April 2009||Khan et al.|
|7524820||April 2009||Khan et al.|
|7560433||July 2009||Khan et al.|
|7662776||February 2010||Khan et al.|
|7786084||August 2010||Benner et al.|
|7795226||September 2010||Benner et al.|
|2002/0064501||May 2002||Khan et al.|
|2002/0147306||October 2002||Lin et al.|
|2003/0049273||March 2003||Gallo et al.|
|2003/0113733||June 2003||Khan et al.|
|2003/0119720||June 2003||Khan et al.|
|2003/0166556||September 2003||Khan et al.|
|2003/0186244||October 2003||Margus et al.|
|2003/0212253||November 2003||Hammond et al.|
|2003/0215434||November 2003||Khan et al.|
|2003/0219425||November 2003||Khan et al.|
|2003/0220257||November 2003||Benner et al.|
|2003/0220258||November 2003||Benner et al.|
|2003/0220259||November 2003||Benner et al.|
|2003/0220260||November 2003||Khan et al.|
|2003/0220261||November 2003||Khan et al.|
|2003/0224995||December 2003||Khan et al.|
|2004/0013661||January 2004||Wensvoort et al.|
|2004/0208885||October 2004||Khan et al.|
|2005/0037430||February 2005||Khan et al.|
|2005/0107314||May 2005||Gorczynski et al.|
|2005/0119184||June 2005||Khan et al.|
|2005/0214943||September 2005||Khan et al.|
|2005/0227925||October 2005||Benner et al.|
|2006/0111292||May 2006||Khan et al.|
|2006/0142205||June 2006||Benner et al.|
|2006/0173162||August 2006||Djurup et al.|
|0 572 688||May., 1997||EP|
|1 138 692||Oct., 2001||EP|
|1 300 418||Apr., 2003||EP|
|1 224 212||Jul., 2003||EP|
|2 706 772||Dec., 1994||FR|
|2 194 886||Mar., 1988||GB|
|WO 92/20795||Nov., 1992||WO|
|WO 96/33218||Oct., 1996||WO|
|WO 97/49721||Dec., 1997||WO|
|WO 98/06742||Feb., 1998||WO|
|WO 98/34631||Aug., 1998||WO|
|WO 98/35691||Aug., 1998||WO|
|WO 99/31227||Jun., 1999||WO|
|WO 99/59617||Nov., 1999||WO|
|WO 00/17348||Mar., 2000||WO|
|WO 01/10907||Feb., 2001||WO|
|WO 01/11048||Feb., 2001||WO|
|WO 0110457||Feb., 2001||WO|
|WO 01/29067||Apr., 2001||WO|
|WO 01/29069||Apr., 2001||WO|
|WO 01/32196||May., 2001||WO|
|WO 01/36454||May., 2001||WO|
|WO 01/51508||Jul., 2001||WO|
|WO 01/68113||Sep., 2001||WO|
|WO 01/72831||Oct., 2001||WO|
|WO 01/83554||Nov., 2001||WO|
|WO 02/085117||Oct., 2002||WO|
|WO 03/029292||Apr., 2003||WO|
|WO 2004/093897||Nov., 2004||WO|
|WO 2005/097163||Oct., 2005||WO|
|WO 2006/069198||Jun., 2006||WO|
Adib-Conquy et al., "NF-.kappa.B Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, vol. 162. cited by other .
Agrawal et al., Acute Renal Fai.quadrature.ure, Amer.quadrature.can Family Physician, 2000, pp. 2077-2088, vol. 61, corresponding to web version of p. 1-12. cited by other .
Arima et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, vol. 22, No. 3. cited by other .
Babu, V. V. Suresh (Synthetic Communcaitons 29 (1)m 79-91, 1999. cited by other .
Baeuerle et al., "Function and Activation of NF-.kappa.B in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, vol. 12. cited by other .
Barton et al., Protective Role of Interleukin 6 in the Lipopolysaccharide-Galactosamine Septic Shock Model, Infection and Immunity, Apr. 1993, pp. 1496-1499, vol. 61, No. 4. cited by other .
Baud et al., Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain, Genes & Development, May 1999, pp. 1297-1308, vol. 13. cited by other .
Brown et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon.quadrature.gamma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, vol. 17. cited by other .
Capizzi, Investigational New Drugs, 1996, 14:249-256. cited by other .
Cillari et al., (Infection and Immunity, vol. 62, No. 6, p. 2649-2652, Jun. 1994). cited by other .
Cui et al., Am. J. Physiol. Integr. Comp. Physiol., 2004, pp. R699-R709, vol. 286. cited by other .
Daemen et al., Ischemia-reperfusion-induced IFN-gamma up-regulation: involvement of IL-12 and IL-13, The Journal of Immunology, 1999, pp. 5506-5510, vol. 162. cited by other .
De Saizieu et al., Journal of Bacteriology, vol. 182, No. 17, pp. 4696-4703, Sep. 2000. cited by other .
Dechend et al., Oncogene, vol. 18, pp. 3316-3323, 1999. cited by other .
Donnahoo et al., Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion, American Journal of Physiology, Sep. 1999, pp. R922-R929, vol. 277, No. 3, Pt. 2. cited by other .
Dwinnell et al., Atlas of Diseases of the Kidney, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12. cited by other .
Eckardt et al., Hypoxia-induced accumulation of erythropoietin mRNA in isolated hepatocytes is inhibited by protein kinase C, Pflugers Archiv., 1994, pp. 21-30, vol. 426. cited by other .
GenBank Accession No. NP.sub.--000728, GI: 4502789, publicly available Apr. 2007. cited by other .
Hierholzer et al., Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock, J. Exp. Med., Mar. 1998, pp. 917-928, vol. 187, No. 6. cited by other .
Huang et al., Ischemia-reperfusion and immediate T cell responses, Cellular Immunology, 2007, pp. 4-11, vol. 248. cited by other .
Husek et al., Rapid screening of urinary proline-hydroxyproline dipeptide in bone turnover studies, Abstract, J. Chromatogr B Analyt Technol Biomed Life Sci., Feb. 5, 2002, pp. 169-174, vol. 767, No. 1. cited by other .
Kalns et al., Biochem. Biophys. Res. Comm., 2002, pp. 41-44, vol. 292. cited by other .
Kalns et al., Biochem. Biophys. Res. Comm., 2002, pp. 506-509, vol. 297. cited by other .
Keeton and Gould, Biological Science, 5th Ed., New York, W.W. Norton & Company, Inc. 1993, p. 4. cited by other .
Lin et al., The Journal of Biological Chemistry, vol. 270, No. 24, pp. 14255-14258, Jun. 1995. cited by other .
Lunardi-Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-a, SIV and associated disease," Nature Medicine, pril 1998, pp. 428-434, vol. 4, No. 4. cited by other .
Merck Index, 17th ed. 1999, pp. 1145-1146, 1841-1848, 2539, 2551. cited by other .
Moayeri et al., Journal of Clinical Investigation, Sep. 2003, pp. 670-682, vol. 112, No. 5. cited by other .
Ohlsson et al., Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock, Nature, Dec. 6, 1990, pp. 550-552, vol. 348. cited by other .
Oka et al., Immunosuppression in organ transplantation, Japanese Journal of Pharmacology, vol. 71, No. 2, pp. 89-100, Jun. 1996. cited by other .
Olszyna et al., Levels of Inhibitors of Tumor Necrosis Factor Alpha and Interleukin 1b in Urine and Sera of Patients with Urosepsis, Infection and Immunity, Aug. 1998, pp. 3527-3534. cited by other .
Partial European Search Report for 02 763 111.8 dated Nov. 23, 2007. cited by other .
Riera et al., Neutrophils accentuate renal cold ischemia-reperfusion injury. Dose-dependent protective effect of platelet-activating factor receptor antagonist, The Journal of Pharmacology and Experimental Therapeutics, 1997, pp. 786-794, vol. 280, No. 2. cited by other .
Roice, M. (Tetrahedron 56 (23), 3725-3734, 2000. cited by other .
Van Holde, Physical Biochemistry, pp. 3947, Prentice-Hall, 1971. cited by other .
Wallraff et al., Urinary Excretion of Amino Acids in Pregnancy, J. Clinc. Invest., 1950, pp. 1542-1544, vol. 29. cited by other .
Werner et al., Experientia vol. 42, p. 521-531, 1986). cited by other .
Wu et al., Gonadotropin-Releasing Hormone (GNRH) Cleavage Products are Involved in the Regulation of GNRH Gene Expression in the GT1-7 Neuronal Cell Line, Society for Neuroscience Abstracts, Nov. 4, 2000, pp. 7.8, XP009091566, vol. 26, No. 1-2. cited by other .
U.S. Appl. No. 11/593,329, filed Nov. 6, 2006, Treatment of Ischemic Events. cited by other .
U.S. Appl. No. 11/600,294, filed Nov. 15, 2006, Oligopeptide Acetate and Formulations Thereof. cited by other .
U.S. Appl. No. 11/975,284, filed Oct. 17, 2007, Treatment for Tumors. cited by other .
U.S. Appl. No. 11/981,491, filed Oct. 30, 2007, Treatment of Iatrogenic Disease. cited by other .
U.S. Appl. No. 11/982,292, filed Oct. 31, 2007, Treatment of Neurologicl Disorders. cited by other .
U.S. Appl. No. 11/986,043, filed Oct. 30, 2007, Peptide Compositions. cited by other .
U.S. Appl. No. 12/001,035, filed Dec. 6, 2007, Gene Regulator. cited by other .
Albini, A., et al., "Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin," 17 Clinical & Experimental Metastasis 739 (1999). cited by other .
Blackwell, Timothy S., et al., "The Role of Nuclear Factor-.kappa.B in Cytokine Gene Regulation," 17 Am. J. Respir. Cell Mol. Biol. 3-9 (1997). cited by other .
Christman et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy, Intens Care Med, 1998, pp. 1131-1138, vol. 24. cited by other .
Connelly et al., Biphasic Regulation of NF-.kappa.B Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-3881, 166, The American Association of Immunologists, USA. cited by other .
Friedlander, Tackling anthrax, Nature, Nov. 8, 2001, pp. 160-161, vol. 414. cited by other .
Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", Nature Medicine, Apr. 1998, vol. 4, No. 4, pp. 428-434. cited by other .
Jyonouchi et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-179, vol. 120. cited by other .
Kachra et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, No. 9. cited by other .
Kanungo et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, vol. 20. cited by other .
Keller, S., et al., "Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells in Vitro," 20(5-6) Placenta, p. A37 (Jul. 1999). cited by other .
Khan, Nisar A., et al., "Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor," 62(12) Human Immunology 1315-1323 (Dec. 2001). cited by other .
Khan, Nisar A., et al., "Inhibition of Septic Shock in Mice by an Oligopeptide From the .beta.-Chain of Human Chorionic Gonadotrophin Hormone," 63(1) Human Immunology 1-7 (Jan. 2002). cited by other .
Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin", AIDS 1997, vol. 11, No. 11, pp. 133-1340. cited by other .
Medzhitov, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, Nov. 2001, pp. 135-145, vol. 1. cited by other .
Muchmore et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, Mar. 1997, pp. 881-886, vol. 118, No. 3. cited by other .
Muchmore et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, Dec. 1984, pp. 1672-1685, vol. 160. cited by other .
Patil, A., et al., "The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study," 87 Acta Neurochir (WIEN) 76-78 (1987). cited by other .
Rohrig et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, vol. 289. cited by other .
Slater, Lewis M., et al., "Decreased Mortality of Murine Graft-VersUS -Host Disease by Human Chorionic gonadotropin,"23(1) Transplantation 103-104 (Jan. 1977). cited by other .
Tak et al., NF-kappa.beta.: a key role in inflammtory diseases, J Clin Invest., 2001, pp. 7-11, vol. 107. cited by other .
Tan et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, vol. 55. cited by other .
Tovey et al., Mucosal Cytokine Therapy: Marked Antiviral and Anti-tumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-921, vol. 19. cited by other .
Wulczyn, F. Gregory, et al., "The NF-kB/Rel and IkB gene families: mediators of immune response and inflammation," 74(12) J. Mol. Med. 749-769 (1996). cited by other .
Yamamoto, Y., et al., "Role of the NF-kB Pathway in the Pathogenesis of Human Disease States," 1(3) Current Molecular Medicine 287-296 (Jul. 2001). cited by other .
Ivanov et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, vol. 39. cited by other .
Khavinson et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland. cited by other .
Khavinson et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, Oct. 2002, pp. 389-392, vol. 134, No. 4. cited by other .
Khavinson et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, Jan. 2004, pp. 78-81, vol. 137, No. 1. cited by other .
Khavinson et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, Jun. 2003, pp. 590-592, vol. 135, No. 6. cited by other .
Khavinson et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, Nov. 2002, pp. 482-484, vol. 134, No. 5. cited by other .
Khavinson et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, Jan. 2002, pp. 1-5, vol. 133, No. 1. cited by other .
Khavinson et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell,"Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, vol. 137, No. 5. cited by other .
Morozov et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, vol. 19, No. 9/10. cited by other.